CSIMarket
 
Aldeyra Therapeutics Inc   (ALDX)
Other Ticker:  
 
 
Price: $4.7550 $-0.74 -13.388%
Day's High: $5.42 Week Perf: -11.94 %
Day's Low: $ 4.57 30 Day Perf: -12.59 %
Volume (M): 796 52 Wk High: $ 6.55
Volume (M$): $ 3,783 52 Wk Avg: $4.04
Open: $5.42 52 Wk Low: $2.43



 Market Capitalization (Millions $) 283
 Shares Outstanding (Millions) 60
 Employees 201
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -45
 Cash Flow (TTM) (Millions $) -75
 Capital Exp. (TTM) (Millions $) 0

Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc. is a biotechnology company that aims to develop next-generation therapies for immune-related disorders, including ocular and rare diseases. The company strives to leverage its proprietary technology platform to design and develop novel drug candidates that can effectively target the underlying causes of these conditions.

Founded in 2004, Aldeyra Therapeutics has made significant progress in advancing its drug pipeline using its innovative technologies. The company's research is primarily centered on developing novel approaches to modulate the immune system to treat diseases, such as dry eye syndrome, allergic conjunctivitis, and Sj'gren's syndrome, a rare autoimmune disorder.

Aldeyra Therapeutics focuses on two key areas:

Developing a pipeline of ophthalmic drug candidates: Aldeyra Therapeutics is developing a range of innovative eye drop solutions to treat various eye conditions, including dry eye syndrome and allergic conjunctivitis. The company has designed an innovative approach to target inflammation in the eye, which is the underlying cause of many eye-related diseases.

Developing a pipeline of drug candidates for rare and immune-mediated diseases: Aldeyra Therapeutics is developing a range of biologic and small molecule therapies to target rare and immune-mediated diseases. The company's lead candidate, ADX-102, is a small-molecule inhibitor that targets inflammation and can potentially treat Sj'gren's syndrome.

The company's drug development pipeline comprises several compounds in various stages of development, including pre-clinical and clinical stages. Aldeyra Therapeutics has a team of experienced drug development professionals, including scientists, medical professionals, and clinicians.

Aldeyra Therapeutics has also secured several partnerships with leading pharmaceutical companies to advance its drug development programs. The company has partnered with Janssen Pharmaceutica and LG Life Sciences to develop its drug candidates for ocular diseases.

In conclusion, Aldeyra Therapeutics is a promising biotech company that is using innovative technologies to develop novel therapies for immune-related disorders. With a strong pipeline of drug candidates in development and strategic partnerships with leading pharmaceutical companies, the company is poised for significant growth and success in the biotech industry.


   Company Address: 131 Hartwell Avenue Lexington 2421 MA
   Company Phone Number: 761-4904   Stock Exchange / Ticker: NASDAQ ALDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APLS        1.49% 
REGN        0.53% 
• View Complete Report
   



Business Update

Reproxalap Aldeyras Bold Resubmission Amidst Financial Strain Offers New Therapeutic Hope for Dry Eye Disease,

Published Thu, Oct 3 2024 11:47 AM UTC

Reproxalap: A New Hope for Dry Eye Disease as Aldeyra Therapeutics Resubmits NDA Amid Financial Challenges'In a promising stride for individuals plagued by dry eye disease, Aldeyra Therapeutics, Inc., a pioneering biotechnology firm, announced a significant development: the resubmission of its New Drug Application (NDA) for topical ocular reproxalap to the U.S. Food and Drug...

Business Update

Aldeyra Therapeutics Spearheads Advancements in Dry Eye Disease Treatment with Positive Phase 3 Trial Results for Rep...

Published Thu, Aug 8 2024 11:47 AM UTC

Abstract:'Aldeyra Therapeutics, Inc. has made significant strides in the field of ophthalmology following the achievement of the primary endpoint in a Phase 3 clinical trial for its investigational drug, reproxalap, aimed at treating dry eye disease (DED). This article provides an overview of the trial outcomes and their implications for the future of dry eye disease treatme...

Announcement

Investigating Potential Violations Understanding the Impact on Aldeyra Therapeutics, Eagle Pharmaceuticals, Blue Ridg...

Published Tue, Jun 25 2024 3:04 PM UTC

In recent news, shareholder rights law firm Johnson Fistel, LLP has initiated an investigation into potential violations of federal and state laws by certain officers of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Blue Ridge Bankshares, Inc. (NYSE: BRBS), and Amplitude, Inc. (NASDAQ: AMPL). This article aims to outline the facts reg...

Business Update

Advancements in RASP Modulators and Preclinical Data in Obesity by Aldeyra Therapeutics

Published Thu, Jun 20 2024 11:47 AM UTC

Aldeyra Therapeutics, a biotechnology company specializing in immune-mediated and metabolic disease treatments, has recently announced significant progress in the development of new RASP (reactive aldehyde species) modulators. In conjunction with an Investor Roundtable, the company revealed promising preclinical data in the field of obesity. This article aims to provide an ...

Business Update

Reproxalap Shows Promise in Phase 3 Clinical Trial for Dry Eye Disease A Step Forward for Aldeyra Therapeutics

Published Thu, Jun 13 2024 12:47 PM UTC

Aldeyra Therapeutics, a pioneering biotechnology company focused on immune-mediated and metabolic diseases, has successfully completed enrollment in a Phase 3 clinical trial for their topical ocular 0.25% reproxalap. The trial aimed to evaluate the effectiveness of this investigational RASP modulator in treating dry eye disease. With the potential for resubmission of a dry e...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com